Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549 · View on ClinicalTrials.gov ↗
Study Summary
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Conditions Studied
Interventions
- DRUG placebo
- DRUG bimekizumab
- DRUG ustekinumab
Study Locations (20)
Other
- Ps0021 40121 — Brussels
- Ps0021 40420 — Liège
- Ps0021 50618 — Mississauga
- Ps0021 50357 — St. John's
- Ps0021 50617 — St. John's
- Ps0021 40748 — Plzen-bory
- Ps0021 40742 — Argenteuil
- Ps0021 40754 — Nantes
- Ps0021 40740 — Bad Bentheim
- Ps0021 40515 — Berlin
- Ps0021 40138 — Bonn
California
- Ps0021 50162 — Fountain Valley
- Ps0021 50161 — Los Angeles
- Ps0021 50196 — Northridge
Texas
- Ps0021 50201 — Arlington
- Ps0021 50355 — Dallas
Florida
- Ps0021 50581 — Miami
Indiana
- Ps0021 50344 — Indianapolis
New York
- Ps0021 50599 — Kew Gardens
South Carolina
- Ps0021 50084 — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2030-11-08 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425549
The ClinicalTrials.gov registry entry for NCT06425549 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 116 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Moderate to Severe Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06425549 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Other, California, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06425549 about?
NCT06425549 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis". The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
What is the current status of trial NCT06425549?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2024-06-25. Estimated completion is 2030-11-08.
What conditions does trial NCT06425549 study?
This clinical trial studies the following conditions: Moderate to Severe Plaque Psoriasis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06425549?
The interventions under investigation include: placebo (DRUG), bimekizumab (DRUG), ustekinumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06425549?
This trial is sponsored by UCB Biopharma SRL, which has 116 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06425549 being conducted?
This trial has 20 study locations across California, Florida, Indiana, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.